Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00602667 Phase I Cisplatin + Cyclophosphamide + Methotrexate + Vincristine Sulfate Cyclophosphamide + Etoposide + Topotecan Cyclophosphamide + Erlotinib + Topotecan Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma Active, not recruiting USA 1
NCT00983398 Phase Ib/II Pegfilgrastim Filgrastim Carboplatin + Melphalan Melphalan, Carboplatin, and Sodium Thiosulfate for Patients With Central Nervous System (CNS) Embryonal or Germ Cell Tumors Active, not recruiting USA 0
NCT01217437 Phase II Irinotecan + Temozolomide Bevacizumab + Irinotecan + Temozolomide Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors Active, not recruiting USA | CAN 3
NCT02095132 Phase Ib/II Adavosertib + Irinotecan Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors Active, not recruiting USA | CAN 0
NCT03173950 Phase II Nivolumab Immune Checkpoint Inhibitor Nivolumab in People With Select Rare CNS Cancers Recruiting USA 0